Barclays
INDP icon

Barclays’s Indaptus Therapeutics INDP Stock Holding History

Barclays’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Hold
0
– – – 6558
2019
Q3 		– Sell
-5
Closed -$14.9K – 6898
2019
Q2 		$49K Buy
+5
New +$63.1K ﹤0.01% 6104

Other funds holding INDP

MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Barclays's INDP Position: Q4 2019 in Review

Barclays held its Indaptus Therapeutics (INDP) position steady in Q4 2019 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #6558.

Barclays first reported a position in INDP in Q2 2019 and has held it in 1 quarter since. The position peaked at $49K in Q2 2019. 25 funds tracked by Wall St. Rank hold INDP as of Q4 2019.

  • Barclays held 0 shares of Indaptus Therapeutics worth $0 as of Q4 2019.
  • Barclays left its Indaptus Therapeutics share count unchanged in Q4 2019.
  • Indaptus Therapeutics made up ﹤0.01% of Barclays's portfolio in Q4 2019, its #6558 holding.
  • Barclays first reported a position in Indaptus Therapeutics in Q2 2019 and has held it in 1 quarter since.
  • Barclays's Indaptus Therapeutics position peaked at $49K in Q2 2019.
  • 25 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q4 2019.

Based on Barclays's 13F filing for Q4 2019, filed 10 Feb 2020.